Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$53.85
neg -1.52
-2.75%
Today's Range: 53.62 - 55.30 | MRK Avg Daily Volume: 10,033,800
Last Update: 08/31/15 - 4:03 PM EDT
Volume: 12,786,092
YTD Performance: -2.50%
Open: $55.00
Previous Close: $55.37
52 Week Range: $45.69 - $63.62
Oustanding Shares: 2,816,635,020
Market Cap: 154,774,094,349
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 6 6 6
Moderate Buy 0 0 0 0
Hold 7 7 7 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.08 2.08 2.00
Latest Dividend: 0.45
Latest Dividend Yield: 3.28%
Dividend Ex-Date: 09/11/15
Price Earnings Ratio: 16.21
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
16.21 16.20 25.43
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-7.25% -7.72% 29.28%
GROWTH 12 Mo 3 Yr CAGR
Revenue -4.10 -0.12 -0.04
Net Income 164.20 0.87 0.23
EPS 176.90 1.02 0.26
Earnings for MRK:
EBITDA 13.37B
Revenue 42.24B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $0.92 $0.91 $3.51 $3.82
Number of Analysts 9 7 11 12
High Estimate $0.96 $0.92 $3.55 $4.01
Low Estimate $0.87 $0.89 $3.45 $3.68
Prior Year $0.90 $0.87 $3.49 $3.51
Growth Rate (Year over Year) 1.73% 4.11% 0.47% 8.92%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
This 15-stock basket offers a stable and growing income stream along with appreciation potential.

Lilly Up Nicely, Merck Down Real Money Pro($)

Eli Lilly (LLY) is up 5% following positive top-line Jardiance results for diabetes. Meanwhile, Merck (MRK) is down 4% on competitive concerns.
Bullish
Aug 13, 2015 | 7:19 AM EDT
MRK was upgraded from Market Perform to Outperform, BMO Capital said. $70 price target. Pipeline should drive strong future growth.&nbs...
Drugmaker has one of the best showings of earnings season.
Drugmaker has one of the best showings of earnings season.

Jensen's Morning Musings Real Money Pro($)

I'm happy as always to be standing in for Doug Kass on the Daily Diary.

The Market Without Memory Real Money Pro($)

After five or six days of market declines, the S&P futures are +12 this morning -- and I'm not surprised.
Competition and lower earnings cloud its future.

Columnist Conversations

Remember $BTC Bitcoin? "Barclays has a team working on about 20 Bitcoin-related experiments." And on that no...
The OIH(Oil Service ETF)is up another 2.5% this afternoon and is now up over 21% from last Monday's close...
Again for emphasis. An important top was likely established in the first half of 2015. Last week might have be...
A few weeks ago I mentioned the massive lockup release to come, on Sept 20 BABA will have over 1.6 bill shares...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.